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As pigment cells undergo melanoma genesis, accentuated 
melanogenesis concurrently occurs in principle. Subsequent 
to the understanding of intrinsic factors controlling both 
processes, we found our selective melanoma neutron capture 
therapy (NCT) using lOB-dopa (melanin substrate) analogue, IOBI-p-boronophenylalanine (l°BI-BPA), followed by 
IOB(n,afLi reaction, induced by essentially harmless thermal 
neutrons, which releases energy of 2.33 MeV to 14,u, the 
diameter of melanoma cells. In vitro/in vivo radiobiological 
analysis revealed the highly enhanced melanoma killing ef­
fect of IOBI_BPA. Chemical and prompt gamma ray spec­
trometry assays of lOB accumulated within melanoma cells 
after IOBI_BPA administration in vitro and in vivo show high 
affinity, e.g., lOB melanoma/blood ratio of 11.5. After suc­
cessfully eradicating melanoma transplanted into hamsters 
P rinciples of Selective Neutron Capture Therapy Thermal neutrons, generated by an atomic reactor, are absorbed easily by the non-radioactive isotope boron-10(IOB). This absorption is known to result in the emission of a-particles and lithium atoms ['oB(n, a)1Li 
reactionJ, which share between them an average total kinetic energy 
of 2.33 MeV [1 J (Fig 1). Due to the limited traveling range of these 
charged particles, the primary radiation injury is confined to a dis­
tance of 10- 14 f.1 from the point of the neutron-activated boron 
atom. This distance is approximately equal to the diameter of an 
individual cancer cell. Therefore, if we can selectively accumulate 
lOB in cancer cells, we can destroy them without serious injury to the 
surrounding normal tissue [2J (Fig 1). 
Melanoma is a highly lethal cancerous growth of pigment cells 
which have the specific function of synthesizing melanin from dopa 
and tyrosine by the action of tyrosinase. As pigment cells undergo 
malignant transformation, their tyrosinase activity usually in­
creases, and this results in an increase of its product, melano-protein. 
If this unique, specific cellular property of melanoma can be utilized 
to concentrate lOB, then a selective, biological, nonsurgical treat­
ment of melanoma can be realized. Furthermore, because the syn­
thesis of unique, specific proteins is not limited to malignant mel a-
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with NCT, we advanced to preclinical studies using sponta­
neously occurring melanoma in Duroc pig skin. We cured 
three melanoma cases, 4.6 to 12 cm in diameter, by single 
neutron capture treatment. Complete disappearance of mela­
noma was obtained without substantial side effects. Acute 
and subacute toxicity as well as pharmacodynamics of IOBI_ 
BPA have been studied in relation to therapeutic dosage re­
quirements. Clinical radiation dosimetry using human phan­
tom has been carried out. Further preclinical studies using 
human melanoma transplanted into nude mouse have been a 
useful model for obtaining optimal results for each mela­
noma type. We recently treated the first human melanoma 
patient with our NCT, using essentially the method for 
Duroc pig melanoma, and obtained similar regression time 
course leading to cure.] Invest Dermato192:321 S-325S, 1989 
noma, but is a property common to many types of human cancers 
(for example, thyroid and squamous cell carcinoma), our aim is to 
develop and establish selective thermal neutron capture treatment 
of malignant melanoma as the prototype for the treatment of these 
types of cancers. 
Melanoma-Seeking lOB-Compounds Since 1972, our idea has 
been to synthesize new tumor-seeking lOB-compounds that possess 
selective affinity for the specific metabolic activity of the target 
cancer cells. 35S-labeled chlorpromazine (CPZ) has been shown to 
bind selectively to melanin, presumably by forming a charge 
transfer complex with an indole nucleus of melanin. Thus 35S_CPZ 
is highly localized in melanoma and in the eyes [3,4J. 
We synthesized two new compounds, molecular hybrids of IOB_ 
CPZ, lOB sodium chlorpromazine undecahydrododecaborate 
(IOBI2-CPZ), and subsequently sodium chlorpromazine nonahy­
drodecaborate, IOBIO-CPZ, which contains twelve and ten boron atoms.per molecule, respectively [5J. IOBI2-CPZ has a unique poly­
hedron structure, with a lOB atom at every apex. 
After confirming the specific affinity and binding of CPZ to 
melanotic melanoma cells [6J, we investigated the specific killing 
effect of IOBI2-CPZ in neutron capture therapy of melanoma using 
in vitro radiobiological assay. IOBI2-CPZ pre-incubation results in a 
definite enhancement of the killing effect compared to neutron 
irradiation only. IOBI2-CPZ was shown to be four times as effective 
in enhancing the killing effect when compared to non-specific lOB 
compounds such as lOB-boric acid [7J. There is no shoulder on the 
survival curve, indicating that no cell repair took place. This highly 
effective IOBI2-CPZ is suitable for the eradication of melanotic ma­
lignant melanoma in thermal neutron capture therapy. 
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7li + a + 2.31 MeV (93.9%) 
4 7l i + y + 0.48 Me V 
Other reactions: 14N(n.p)4c, H(n,y)D 
Figure 1. Schematic drawing of thermal neutron capture therapy of malig. 
nant melanoma cells using IOB(n, a)1Li reaction. 
IOBI-BPA Neutron Capture Therapy In addition to melanin­
seeking lOB-chlorpromazine compounds, we also investigated me­
lanogenesis-seeking compounds. These would specifically accumu­
late in melanoma cells that have low or no melanin content, but 
have tyrosinase activity, such as the young, post-mitotic cells. 
Melanin is formed from tyrosine or dopa by the action of tyrosin­
ase. If boron-labeled dopa is administered, the boron uptake is pro­
portional to the rate of melanin synthesis. Thus, in co-operation 
with Drs. Kakihana, Okamoto, and Yoshino [8]' we synthesized 
four hybrid compounds of lOB and the tyrosinase substrate, dopa 
(Fig 2), of which IOBI-para-boronophenylalanine hydrochloride 
(l°BI-BPA), described by Snyder [9] in 1958, is the most promising. 
We investigated the enhanced melanoma-killing effect of 10BI_ 
BPA in neutron capture therapy. This enhanced killing effect was 
confirmed by in vitro radiobiological assay and by in vivo experi­
ments using Greene's melanoma proliferating in Syrian golden 
hamsters. These results led us to conduct pre-clinical therapeutic 
experiments prior to initiating clinical trials. We used the thermal 
columns of the Kyoto University Nuclear Reactor Heavy Water 
Facility (KUR) and of the Musashi Institute of Technology Reactor 
(MIR) as the source of thermal neutrons. 
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Figure 2. Molecular hybrid compounds of lOB and dopa. We have already 
synthesized the first three and are working on the last one. 
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Prior to irradiation the neutron field was modified for medical 
and biological purposes by the development of a bismuth scatterer 
by Dr. Kanda, Dr. Kobayashi, and other physicists of our group [10]. 
This reduced the gamma-to-neutron ratio by one order of magni­
tude. The next point was to evaluate, in co-operation with our 
physicist colleagues, the iso-dose distribution of radiation energy 
within a human body. Therefore, an acrylic lifesize model of a 
human thigh was made, containing a ping pong ball to represent the 
melanoma at the subcutaneous level. Rossi's tissue equivalent solu­
tion was put into both with the addition of 20 or 40 I1gj g of lOB in 
the melanoma model. When we added these amounts of lOB and 
irradiated at KUR with 1,000 kW for 30 mins, we found that the 
absorbed dose distribution at the outer surface of the melanoma 
model was 2.5 and 4 times that of the outer surface of the thigh 
model, respectively [10]. 
In Vitro Radiobiological Studies Prior to in vivo experiments, 
an in vitro radiobiological assay was carried out to evaluate the 
specific enhanced melanoma cell killing effect of IOBI-BPA in neu­
tron capture therapy. Cultured B-16 melanoma cells were pre-incu­
bated for 20 h both with and without IOBI-BPA. Then each group 
was irradiated on parallel graphite tables at varying distances from 
the bismuth surface of the reactor, and cell survival curves were 
formulated (Fig 3). As compared to neutron irradiation alone, a 
significantly enhanced specific killing effect was obtained by pre­
incubating with IO l1g of 10BI_BPA. The same amount (lOl1g) of 
BPA containing natural boron (nBI-BPA) produced a distinctly 
lower killing effect. Because 10BI_BPA contains approximately 5 
times more lOB atoms than nBI-BPA, the increased density of 
10B(n,a)7Li reactions is the main factor responsible for the enhanced 
killing effect. 
Dynamics of lOB Dosimetry in Melanomas To develop spe­
cific neutron capture therapy as a treatment for melanoma, the 
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Figure 3. Fraction of surviving melanoma cells after undergoing thermal 
neutron irradiation alone or in conjunction with IOB,-BPA or "B,-BPA 
pre-incubation. Cells were pre-incubated for 20 h in IOB,-BPA followed by 
either 6 h (e) or 1 h (()) of post-incubation with fresh normal medium. 
Cells were pre-incubated in "B,-BPA for 20 h and post-incubated for 6 h 
(<,,». The number of colonies was counted to obtain the dose survival curve. 
Each point represents the mean value of triplicate plates; the standard errors 
ranged from 2.2% to 9.5%. 
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quantitative analysis of lOB accumulation in melanoma in compari­
son with other organ systems must be carried out. This has been 
done in relation to both the melanomas' melanogenic activity, and 
to the various kinds of lOB compounds. The boron concentrations in 
melanoma, blood, and other organs were determined by colorime­
tric assay [11] at various intervals after systemic injection. The mela­
noma to blood ratio of lOB 14 h after administration was 10: 1, and 
the liver to blood ratio was 1: 1 [13]. At 28 h, the melanoma to 
blood ratio of lOB was 11.5: 1 and the melanoma to liver ratio was 
15: 1, indicating an optimal time for neutron capture therapy [12]. 
Figure 4 shows representative results, displaying the tissue/blood 
ratios of boron concentration as determined by colorimetric assay. 
The specific affinity of IOBI_BPA for melanoma can be elucidated 
further by performing density gradient fractionations of melanoma 
cells, and isolating the melanosome fraction. The melanosome, the 
cellular organelle that synthesizes and contains melanin, demon­
strates a greater concentration of lOB than any other subcellular 
particulate fraction [14]. 
Because the amount of secondary gamma radiation emitted after 
thermal neutron irradiation is directly proportional to lOB concen­
tration in tissues, we used this fact to determine lOB concentration in 
melanomas in situ. In co-operation with Dr. Kanda and Dr. Ko­
bayashi [15], we have developed a system to detect neutron-induced 
prompt gamma rays in lOB-containing melanoma and to measure 
the time course of lOB accumulation within tumors in situ in patients 
without biopsy. This confirmed our boron chemical assay, showing 
high level, selective accumulation of IOBI_BPA into Green's mela­
notic melanoma in Syrian golden hamster skin in comparison to 
surrounding normal skin [14]. 
In parallel with these chemical and physical lOB dosimetries, dis­
tribution of lOB in melanoma compared to other organs in the whole 
body has been visualized by the use of a-track autoradiography [16]. 
The a-track method was also used in order to quantitate in situ the 
number of (n,a) reactions induced within a melanoma. In the Duroc 
pig melanoma, discussed below, there was 2711g of IOB/g mela­
noma as measured by this method. 
In Vivo Radiotherapeutic Studies Based on the above, we 
tested the in vivo therapeutic effects ofloBI-BPA enhanced neutron 
capture therapy using Greene's melanoma transplanted into the 
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Figure 4. Time-course of the tissue/blood ratios of boron concentration 
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subcutaneous tissue of Syrian (golden) hamsters and found a hereto­
fore unobserved melanoma killing effect. The melanoma growth 
curves of the hamster group irradiated with thermal neutrons for 
2 h (1.1 X 1013 n/cm2) without prior administration of IOBI_BPA 
were moderately suppressed compared to the control unirradiated 
hamster group. However, the tumor growth curves of hamster mel­
anomas treated with the same dosage of neutron irradiation com­
bined with an intramuscular administration of 40 mg of IOBI-BPA 
8 h before irradiation, showed a complete regression in most of the 
melanomas [17]. 
Preclinical Therapeutic Experiments The success of our labo­
ratory experiments led us to initiate preclinical therapeutic experi­
ments using spontaneously occurring malignant melanoma in 
Duroc pig skin. General anesthesia, controlled from a distance, was 
used to keep the subject in front of the reactor. After six experiments 
[17], we finally induced complete resolution of a melanoma in a pig 
with a single irradiation of 1.56 X 1013 n/cm2 and a peri-lesional 
injection of 6 g of IOBI-BPA. The tumor showed a consistent, per­
sistent reduction in size leading to complete disappearance 65 days 
(d) after irradiation. There was minimal damage to surrounding 
skin. In order to confirm the apparent cure we continued to observe 
the pig for 174 d, and then performed an autopsy. No melanoma 
was found on either macroscopic or microscopic examination. 
We had a second success in treating a Duroc pig melanoma. This 
melanoma, 12 cm in diameter, (Fig SA) was 10 times as large as the 
one cured in the first case. It occurred spontaneously on the right 
lateral abdomen of a 2-year-old female pig. We gave her two peri­
lesional injections of 5 g each opoBI-BPA, one 19 h and the other 
20 min prior to commencing a single irradiation which lasted for 
4 h at 100 k W. Figure 6 shows the dose distribution of neutron and 
y-ray irradiation energy as actually measured on melanoma and 
surrounding tissues, as well as on distant body surfaces. In this case, 
as in the previous case, ulceration occurred after 14 d. Figure SB,C, 
shows the clinical appearance of the pig 62 and 115 d after irradia­
tion. This shows the regression leading to a complete cure of mela­
noma with depigmentation of the skin at the melanoma site. No 
obvious side effects were observed, and the blood count and liver 
function tests were found to remain within normal limits after the 
treatment. 
After we achieved therapeutic success in treating naturally occur­
ring cutaneous melanoma by a single irradiation of thermal neu­
trons, we performed a control experiment. We covered one-half of 
a Duroc pig melanoma with an LiF sheet collimator and then ad­
ministered neutron capture therapy, this time using a single sys­
temic administration of 6 g IOBI_BPA intramuscularly 2.5 h prior to 
3 h of irradiation at 100 kW. The dosimetry of thermal neutron 
radiation on the treated and control areas of the melanoma were 
measured on the surface as 18 X 1012 and 0.66 X 1012 n/cm2, re­
spectively. 178 d after irradiation, complete regression of the lesion 
was observed only on the treated side, although the covered side of 
the melanoma also showed some regression corresponding to ab­
sorbed radiation energy on its surface and interior. Accordingly, 
radiation energy isodose curves within a melanoma, derived from 
phantom and simulation experiments done by our nuclear physicist 
colleagues, revealed a curved pathway for thermal neutrons inside 
the melanoma beneath a collimator. 
Our overall program to develop a comprehensive therapeutic 
scheme for curing human melanoma led us to advance our studies in 
several directions simultaneously. First, we treated human mela­
noma transplanted into nude mice. Melanoma growth curves reveal 
substantial response but not total resolution after thermal neutron 
irradiation for 60 min at 100 kW together with i.p. injection of 
10 mg IOBI_BPA 4 h prior to irradiation. This was in contrast to 
control mice and to neutron alone, or compound alone, treated 
mice. Second, acute toxicity tests were carried out and the LDso was found to be 710 mg/kg for female mice. Third, we have carried out 
further therapeutic data comparison between our capture therapy 
and conventional electron beam therapy based on the criteria of 
growth delay time using Greene's melanoma-bearing Syrian golden 
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h.llllSter. The "Tn value, the �rowth delay time, is defincd as the 
numhcr of dan required for a tumor to rl'g�ow to its initial volume 
aftn a theLlpeutic intnvention. In order to evaluate growth de by 
time we avoided complete remission of melanoma by reducing 
IIIB,_BI'A dmage to 50'Vc) of the dose administert'd in our standard 
thnapeutic experiment to 20 mg per hamster. Growth delay times 
of S .md 11 d with neutron alone, and neutron plus i.p. injection of 
1('B,-BI'/\, respectively, were measured. Melanoma growth delay 
times hv conventional elecrron bcam therapy indicate that the " T " 
v;duc of 11 d corresponds to 2500 rads [1 Y]. 
hn.dly, we checked the distribution of radiation energy to which 
the whole body is exposed following a local exposure using a human 
plLlntom containing human bone ,md Rossi solution [20]. As 30% 
to 40"/" of melanomas amongJapanese occur on the sole in the form 
of acr,d-lentigillous or nodular type of malignant nlC'lanoma, we 
h;lve SL,kered this as the initial urget lesion for our thnapy. Radia-
TilE J OUItNAL Of' INVESTI(;ATIVE IlERMATOLO(;Y 
c 
Figure S. II: The clinic.d appl'aLlIlCl' of naturally ()ccurrin� 111.lli�l1ant 111cl­
;lnOlll;I ill the skill of a I hlfoc pig hefore trcatInent: B: regression of the 
111Cl.llloilU 62 dafter trcatlllcnt: C: cOlllplcrc disappcarJl1cc of Illcbnolna 
\virh dcpigllH'lltJrioll 11:1 d Jftcr trCJtlllcnt. 
tion exposure analysis has already bet'n carried out, and the amount 
of ncutron and ;'-rays was determined at various points on the body 
and t�)llJ1d to he within acceptable limits. Whcn 6 X 1012 n/cm2 is 
given to a melanoma on the solt, the exposure dose measured at the 
face is 6.4 X 109 n/Cl]]2. This is approximately 1/1000 of the dose 
delivefl,d to the primary treatment ar('a. We can further reduce this 
exposure bv the usc of better collimation, and direct shielding of 
non-targ('t areas of the body. Furthermore, because the amount of 
energy actually absorbed depends primarily on the number of 
IOB(n,n)"Li reactions, and this in turn depends on IOB,-BPA con­
centration, the selective accumulation of IOB_BPA by the melanoma 
causes the greatest amount of absorhed radiation energy to be lim­
ited to the target tissue. Estahlishment of a clinical therapeutic 
method for curing human melanoma with a single irradiation of 
thermal neutrons is underway through the correlation of biophysi­
cal, biochemical, hiological, and therapeutic data analysis. 
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Figure 6. Measured dose distribution of neutron and ),-ray irradiation en­
erl(Y on melanoma and surrounding skin. as well as distant body surface of 
the treated pil( shown in Fil( 5. (This work was done in cooperation with K. 
Sato and H. Fukuda.) 
v cry recently, we have treated the first human melanoma [21] 
with our capture therapy using essentially the same method as for 
the Duroc pig melanoma. The regression of the treated human 
melanoma leading to cure has followed an almost identical time 
course to that of our successfully treated 12 cm diameter Duroc pig 
melanoma described above. 
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